Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.42
ARIA's Cash to Debt is ranked higher than
59% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ARIA: 1.42 )
ARIA' s 10-Year Cash to Debt Range
Min: 0.8   Max: No Debt
Current: 1.42

Equity to Asset 0.42
ARIA's Equity to Asset is ranked higher than
57% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARIA: 0.42 )
ARIA' s 10-Year Equity to Asset Range
Min: -2.2   Max: 0.89
Current: 0.42

-2.2
0.89
F-Score: 3
Z-Score: -3.45
M-Score: 2.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -600.44
ARIA's Operating margin (%) is ranked higher than
58% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ARIA: -600.44 )
ARIA' s 10-Year Operating margin (%) Range
Min: -526300   Max: 58.61
Current: -600.44

-526300
58.61
Net-margin (%) -601.74
ARIA's Net-margin (%) is ranked higher than
57% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ARIA: -601.74 )
ARIA' s 10-Year Net-margin (%) Range
Min: -493975   Max: 194.03
Current: -601.74

-493975
194.03
ROE (%) -147.78
ARIA's ROE (%) is ranked higher than
53% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. ARIA: -147.78 )
ARIA' s 10-Year ROE (%) Range
Min: -204.64   Max: 133.04
Current: -147.78

-204.64
133.04
ROA (%) -73.92
ARIA's ROA (%) is ranked higher than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ARIA: -73.92 )
ARIA' s 10-Year ROA (%) Range
Min: -123.07   Max: 71.02
Current: -73.92

-123.07
71.02
ROC (Joel Greenblatt) (%) -251.49
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. ARIA: -251.49 )
ARIA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2753.99   Max: 1490.69
Current: -251.49

-2753.99
1490.69
Revenue Growth (%) -45.70
ARIA's Revenue Growth (%) is ranked higher than
59% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ARIA: -45.70 )
ARIA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 214.8
Current: -45.7

0
214.8
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ARIA Guru Trades in Q2 2013

Columbia Wanger 4,174,000 sh (unchged)
Stanley Druckenmiller Sold Out
Jim Simons Sold Out
Daniel Loeb Sold Out
Louis Moore Bacon 75,000 sh (-72.73%)
Steven Cohen 71,450 sh (-79.87%)
» More
Q3 2013

ARIA Guru Trades in Q3 2013

Manning & Napier Advisors, Inc 504,530 sh (New)
Columbia Wanger 5,291,000 sh (+26.76%)
Steven Cohen 56,180 sh (-21.37%)
Louis Moore Bacon 50,000 sh (-33.33%)
» More
Q4 2013

ARIA Guru Trades in Q4 2013

Chuck Royce 686,602 sh (New)
George Soros 1,950,000 sh (New)
Paul Tudor Jones 18,432 sh (New)
Steven Cohen 93,800 sh (+66.96%)
Manning & Napier Advisors, Inc Sold Out
Columbia Wanger Sold Out
Louis Moore Bacon Sold Out
» More
Q1 2014

ARIA Guru Trades in Q1 2014

Jim Simons 2,248,846 sh (New)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 516,602 sh (-24.76%)
George Soros 500,000 sh (-74.36%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 Reduce -74.36%0.08%$6.46 - $8.99 $ 6.18-20%500000
George Soros 2013-12-31 New Buy0.11%$2.2 - $18.8 $ 6.1820%1950000
Daniel Loeb 2013-06-30 Sold Out 0.94%$16.32 - $19.77 $ 6.18-65%0
Daniel Loeb 2012-12-31 Add 85.19%0.4%$18.93 - $25.16 $ 6.18-72%2500000
Daniel Loeb 2012-09-30 Reduce -35.71%0.39%$17.11 - $24.21 $ 6.18-69%1350000
Daniel Loeb 2012-06-30 New Buy1.1%$14.6 - $17.82 $ 6.18-62%2100000
George Soros 2012-06-30 Sold Out 0.15%$14.6 - $17.82 $ 6.18-62%0
George Soros 2012-03-31 New Buy0.15%$12.73 - $16.32 $ 6.18-55%635000
George Soros 2011-12-31 Sold Out 0.07%$8.03 - $12.5 $ 6.18-44%0
George Soros 2011-09-30 New Buy0.07%$7.63 - $13.34 $ 6.18-41%496847
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.70
ARIA's P/B is ranked higher than
69% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. ARIA: 7.70 )
ARIA' s 10-Year P/B Range
Min: 1.69   Max: 125.8
Current: 7.7

1.69
125.8
P/S 22.52
ARIA's P/S is ranked higher than
71% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. ARIA: 22.52 )
ARIA' s 10-Year P/S Range
Min: 1.71   Max: 705
Current: 22.52

1.71
705
EV-to-EBIT -3.51
ARIA's EV-to-EBIT is ranked higher than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARIA: -3.51 )
ARIA' s 10-Year EV-to-EBIT Range
Min: 2.3   Max: 13.4
Current: -3.51

2.3
13.4
Current Ratio 2.96
ARIA's Current Ratio is ranked higher than
67% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ARIA: 2.96 )
ARIA' s 10-Year Current Ratio Range
Min: 0.62   Max: 15.1
Current: 2.96

0.62
15.1
Quick Ratio 2.96
ARIA's Quick Ratio is ranked higher than
69% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ARIA: 2.96 )
ARIA' s 10-Year Quick Ratio Range
Min: 0.52   Max: 14.95
Current: 2.96

0.52
14.95

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.20
ARIA's Price/Tangible Book is ranked higher than
75% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. ARIA: 8.20 )
ARIA' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 1133
Current: 8.2

0.86
1133
Price/Median PS Value 0.30
ARIA's Price/Median PS Value is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ARIA: 0.30 )
ARIA' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 11.33
Current: 0.3

0.01
11.33
Earnings Yield (Greenblatt) 31.40
ARIA's Earnings Yield (Greenblatt) is ranked higher than
87% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARIA: 31.40 )
ARIA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.5   Max: 42.7
Current: 31.4

7.5
42.7
Forward Rate of Return (Yacktman) -9.35
ARIA's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. ARIA: -9.35 )
ARIA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -21.7   Max: -4.2
Current: -9.35

-21.7
-4.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:APS.Germany
Ariad Pharmaceuticals was organized as a Delaware corporation in April 1991. It develops targeted therapies to treat solid tumors and hematologic cancers, as well as the spread of primary tumors to distant sites. are building a pipeline of product candidates that has the potential to expand and improve upon current treatment options for patients with cancer. Each of its product candidates -- ponatinib, AP26113 and ridaforolimus- was discovered internally by scientists based on expertise in cell-signaling, cancer biology and structure-based drug design. Ponatinib is an investigational, pan BCR-ABL inhibitor that it believe has potential applications in various hematological cancers and solid tumors. It has completed enrollment in pivotal Phase 2 clinical trial in patients with resistant or intolerant chronic myeloid leukemia, or CML, and Philadelphia positive acute lymphoblastic leukemia, or Ph+ ALL; AP26113 is an investigational dual inhibitor of anaplastic lymphoma kinase, or ALK, and Ridaforolimus is an investigational mTOR inhibitor that it discovered internally and later licensed in 2010 to Merck, Sharpe & Dohme Corp., or Merck. epidermal growth factor receptor, or EGFR; and The company's drug discovery program builds on its expertise in cell signaling, cancer biology, structure-based drug design and computational chemistry in designing and characterizing small-molecule drugs, such as deforolimus and AP24534, to treat disease. The company pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., Celgene Corporation and Pfizer, Inc., are developing and marketing drugs to treat cancer.
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
creiter note on ARIA Jan 03 2010 


More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 24 2014
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% Jul 24 2014
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results Jul 16 2014
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results Jul 16 2014
ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe Jul 14 2014
ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today Jul 08 2014
UCB, Dermira Sign Cimzia Dermatology Deal Jul 07 2014
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock Jul 07 2014
Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session Jul 03 2014
Amgen Gets Breakthrough Therapy Status for Leukemia Drug Jul 02 2014
Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% Jul 02 2014
Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session Jul 02 2014
Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% Jul 01 2014
UCB's Vimpat Positive for Partial-Onset Seizures Jun 30 2014
QLT Inc. (QLTI) in Focus: Stock Surges 14.63% Jun 27 2014
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 26 2014
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 24 2014
Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% Jun 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide